diacerein 1% ointment
Sponsors
Castle Creek Pharmaceuticals, LLC
Conditions
Dystrophic Epidermolysis BullosaEpidermolysis BullosaEpidermolysis Bullosa (EB)Epidermolysis Bullosa SimplexHealthyJunctional Epidermolysis Bullosa
Phase 1
To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)
CompletedNCT03472287
Start: 2018-05-18End: 2019-02-14Updated: 2020-02-10
A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects
CompletedNCT03472547
Start: 2018-01-15End: 2018-03-03Updated: 2019-10-21
A 21 Day Irritation Study in Healthy Volunteers With Diacerein 1% Ointment
CompletedNCT03472534
Start: 2018-01-09End: 2018-01-30Updated: 2020-02-05
A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers
CompletedNCT03473184
Start: 2017-12-12End: 2017-12-15Updated: 2020-02-10
A 6-Week Study to Evaluate the Photoallergic Potential of Diacerein 1% Ointment in Healthy Volunteers
CompletedNCT03473197
Start: 2018-01-08End: 2018-03-09Updated: 2020-02-05
Phase 2
Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)
TerminatedNCT03154333
Start: 2017-06-01End: 2018-10-31Updated: 2019-11-05
Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
CompletedNCT03389308
Start: 2017-12-01End: 2020-04-17Updated: 2020-09-16